Continues to build capacity for long-term growth; employee base crosses 12,000 Elxsians Tata Elxsi (BSE: 500408 | NSE: TATAELXSI), amongst the world’s leading providers of design led technology services, announced its first quarter results for the period ending 30th June 2023. Highlights of the Quarter Ended June
Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Micafungin for Injection, 50 mg/vial and 100 mg/vial, single-dose vials (USRLD: Mycamine®). Micafungin for Injection is indicated to treat variety of fungal infections. It
Lipid abnormalities were determined basis the mentioned cut-offs recommended by LAI (Lipid Association of India): HDL (High-density lipoprotein) < 40 mg/dL for males HDL<50 mg/dL for females, LDL (Low-density lipoprotein) ≥130 mg/dL, total cholesterol ≥200 mg/dL, TG (Triglycerides) ≥150 m/dL The findings of this
